Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 47 resultados

VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado

MC4DD: Macrocycles for Drug Discovery Better drugs are one of the most efficient and sustainable ways to improve health care, a key strategic orientation in Horizon Europe. New d...
2024-07-10 - 2028-10-31 | Financiado

PIA: Photocatalytic Industrial Applications SANOFIAVENTIS DEUTSCHLAND GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2023-DN-01 The European Union has been challenged to contribute to the global aim of providing sustainable solutions to the current and future needs on...
2024-05-30 - 2028-12-31 | Financiado

ISOBIOTICS: Isotopic Labeling of Biotherapeutics SANOFIAVENTIS DEUTSCHLAND GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatmen...
2022-07-14 - 2027-01-31 | Financiado

RealHOPE: Real World Handling of Protein Drugs Exploration Evaluation and Education SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage RealHOPE will create an understanding of the real-life handling of protein drugs in hospital pharmacy, clinics and in the hands of patients...
2021-07-05 - 2025-06-30 | Financiado

INNODIA HARVEST: Translational approaches to disease modifying therapy of type 1 diabetes HARVESTing the fruits of... SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Building on the strong foundations of INNODIA, with its unique, Europe-wide clinical and basic research network for the study of type 1 diab...
2020-04-16 - 2024-04-30 | Financiado

ImmUniverse: Better control and treatment of immune mediated diseases by exploring the universe of microenvironme... SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enorm...
2019-12-17 - 2024-12-31 | Financiado

3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in... SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | Financiado

BIOMAP: Biomarkers in Atopic Dermatitis and Psoriasis SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molec...
2019-02-27 - 2025-03-31 | Financiado

ESCulab: European Screening Centre Unique Library for Attractive Biology SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific...
2018-12-18 - 2023-11-30 | Financiado

iConsensus: Integrated control and sensing platform for biopharmaceutical cultivation process high throughput de... SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage IConsensus will provide innovative analytical, hardware, software and high-throughput (HTP) solutions for the development, monitoring and co...
2018-06-21 - 2022-10-31 | Financiado

Hypo-RESOLVE: Hypoglycaemia REdefining SOLutions for better liVEs SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Diabetes is one of the most prevalent global non-communicable diseases, affecting 60 million people in Europe, 10% of whom with type 1 diab...
2018-04-30 - 2023-10-31 | Financiado

LITMUS: Liver Investigation Testing Marker Utility in Steatohepatitis SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liv...
2017-10-09 - 2024-02-29 | Financiado

eTRANSAFE: Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Drug safety assessment is a knowledge-intensive process that demands advancement in data handling methods and tools for facilitating data sh...
2017-09-12 - 2023-02-28 | Financiado

RTCure: Rheuma Tolerance for Cure SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progressio...
2017-08-25 - 2023-08-31 | Financiado

IB4SD-TRISTAN: Imaging Biomarkers IBs for Safer Drugs Validation of Translational Imaging Methods in Drug Safety... SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage 1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation. We are internationally recognized exp...
2017-03-10 - 2024-12-31 | Financiado

BEAt-DKD: Biomarker Enterprise to Attack DKD Sofia ref. 115974 SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached e...
2016-12-20 - 2023-08-31 | Financiado

RHAPSODY: Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification S... SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, info...
2016-06-07 - 2021-09-30 | Financiado

MAST4HEALTH: Mastiha treatment for healthy obese with NAFLD diagnosis MAST4HEALTH . SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-MSCA-RISE-2015 MAST4HEALTH is set on the concept of a multidisciplinary approach to assess a non-pharmacological intervention for managing NAFLD/NASH, one...
2015-12-16 - 2020-02-29 | Financiado

INNODIA: Translational approaches to disease modifying therapy of type 1 diabetes an innovative approach tow... SANOFIAVENTIS DEUTSCHLAND GMBH participó en un H2020: H2020-JTI-IMI2-2014-01-two-stage Preclinical type 1 diabetes (T1D) research has made important advances in recent years, but less progress has been made in translating findi...
2015-12-07 - 2023-10-31 | Financiado